ARDIZZONI, ANDREA
ARDIZZONI, ANDREA
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
2022-01-01 Andrini, E.; Lamberti, G.; Mazzoni, F.; Riccardi, F.; Bonetti, A.; Follador, A.; Artioli, F.; Genova, C.; Barbieri, F.; Frassoldati, A.; Brighenti, M.; Colantonio, I.; Pasello, G.; Ficorella, C.; Cinieri, S.; Tiseo, M.; Gelsomino, F.; Tognetto, M.; Rihawi, K.; Ardizzoni, A.
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study
2025-01-01 Lamberti, Giuseppe; Rihawi, Karim; Mazzoni, Francesca; Riccardi, Ferdinando; Follador, Alessandro; Tiseo, Marcello; Frassoldati, Antonio; Colantonio, Ida; Bonetti, Andrea; Genova, Carlo; Giardina, Donatella; Bertolini, Federica; Cinieri, Saverio; Pasello, Giulia; Brighenti, Matteo; Andrini, Elisa; Tognetto, Michele; Boni, Luca; Ardizzoni, Andrea
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer
1996-01-01 Venturini, Marco; Del Mastro, Lucia; Testore, Franco; Danova, Marcoc; Garrone, Ornella; Lanfranco, Claudio; Latini, Fabio; Sertoli, Mario R.; Lionetto, Rita; Queirolo, Paola; Ardizzoni, Andrea; Rosso, Riccardo
Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma
1993-01-01 Garrone, O.; Del Mastro, L.; Mariani, G. L.; Ardizzoni, A.; Venturini, M.; Rosso, R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale | 1-gen-2022 | Andrini, E.; Lamberti, G.; Mazzoni, F.; Riccardi, F.; Bonetti, A.; Follador, A.; Artioli, F.; Genova, C.; Barbieri, F.; Frassoldati, A.; Brighenti, M.; Colantonio, I.; Pasello, G.; Ficorella, C.; Cinieri, S.; Tiseo, M.; Gelsomino, F.; Tognetto, M.; Rihawi, K.; Ardizzoni, A. | |
| Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study | 1-gen-2025 | Lamberti, Giuseppe; Rihawi, Karim; Mazzoni, Francesca; Riccardi, Ferdinando; Follador, Alessandro; Tiseo, Marcello; Frassoldati, Antonio; Colantonio, Ida; Bonetti, Andrea; Genova, Carlo; Giardina, Donatella; Bertolini, Federica; Cinieri, Saverio; Pasello, Giulia; Brighenti, Matteo; Andrini, Elisa; Tognetto, Michele; Boni, Luca; Ardizzoni, Andrea | |
| Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer | 1-gen-1996 | Venturini, Marco; Del Mastro, Lucia; Testore, Franco; Danova, Marcoc; Garrone, Ornella; Lanfranco, Claudio; Latini, Fabio; Sertoli, Mario R.; Lionetto, Rita; Queirolo, Paola; Ardizzoni, Andrea; Rosso, Riccardo | |
| Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma | 1-gen-1993 | Garrone, O.; Del Mastro, L.; Mariani, G. L.; Ardizzoni, A.; Venturini, M.; Rosso, R. |